ArticleBritish journal of cancer2013

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.

W T Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.